NCT05385757

Brief Summary

Childhood uveitis (inflammation inside the eye) is an uncommon disorder that carries the risk of blindness. Inadequate treatment of active inflammation has been shown to be related to a poor outcome. There has been no population-based, prospective longitudinal study of all-cause childhood uveitis, with resultant limitations in the evidence base used to counsel affected families, balance treatment decisions, or plan further research. The aim of the study is to describe the characteristics of childhood-onset uveitis and describe outcomes. The investigators shall also aim to identify the socio-demographic, clinical, biological and treatment-related determinants of outcome. Early (1-2 years following diagnosis) outcomes will be described in the first instance: However, through the creation of a national inception cohort, the investigators shall enable longer-term studies of outcome for affected children and families. There will be no change to routine clinical care.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
250

participants targeted

Target at P75+ for all trials

Timeline
7mo left

Started Oct 2020

Longer than P75 for all trials

Geographic Reach
1 country

31 active sites

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress91%
Oct 2020Dec 2026

First Submitted

Initial submission to the registry

October 16, 2020

Completed
6 days until next milestone

Study Start

First participant enrolled

October 22, 2020

Completed
1.6 years until next milestone

First Posted

Study publicly available on registry

May 23, 2022

Completed
3.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2025

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2026

Expected
Last Updated

October 4, 2024

Status Verified

September 1, 2024

Enrollment Period

5.1 years

First QC Date

October 16, 2020

Last Update Submit

October 3, 2024

Conditions

Keywords

Quality of lifeChildProspective CohortVision

Outcome Measures

Primary Outcomes (2)

  • Incidence of ocular complications

    New incident of sight threatening ocular complications, including glaucoma, cataract and macular oedema

    Up to 3 years

  • Pediatric Quality of Life Inventory Score

    Quality of life (patient reported outcomes) using Pediatric Quality of Life Inventory (PedsQL) in which items are reversed scored and linearly transformed to a 0-100 scale, so that higher scores indicate better HRQOL (Health-Related Quality of Life)

    Up to 3 years

Secondary Outcomes (4)

  • Corticosteroid exposure

    Up to 3 years

  • Attainment of disease control

    Up to 3 years

  • Health Utility

    Up to 3 years

  • Change in Pediatric Quality of Life Inventory Score

    Over one year from baseline to year one

Study Arms (1)

Childhood Uveitis

Children \<18 years old newly diagnosed with non-infectious uveitis

Eligibility Criteria

AgeUp to 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Children those aged under 18 years old (at diagnosis) who are newly diagnosed with uveitis newly diagnosed with uveitis (within previous 6 months)

You may qualify if:

  • Children newly diagnosed with uveitis (within previous 6 months)
  • Age \< 18years

You may not qualify if:

  • Uveitis due to malignancy
  • Uveitis due to ocular trauma (including iatrogenic, ie intraocular surgery)
  • Uveitis due to confirmed ocular infection
  • Children with developmental disorders or impairments which prevent their self-report of their function level or quality of life

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (31)

Belfast Royal Victoria Hospital NHS Foundation Trust

Belfast, BT9 7AB, United Kingdom

Location

Birmingham Women's and Children's Hospital NHS Foundation Trust

Birmingham, B4 6NH, United Kingdom

Location

Royal Bournemouth Christchurch Hospitals NHS Foundation Trust

Bournemouth, BH7 7DW, United Kingdom

Location

Bradford Teaching Hospitals NHS Foundation Trust

Bradford, BD9 6RJ, United Kingdom

Location

University Hospitals Bristol NHS Foundation Trust

Bristol, BS1 3NU, United Kingdom

Location

Cambridge University Hospital NHS Foundation Trust

Cambridge, CB2 0QQ, United Kingdom

Location

Cardiff and Vale University Health Board Hospitals

Cardiff, CF14 4XW, United Kingdom

Location

Mid Essex Hospital Trust

Chelmsford, CM1 7ET, United Kingdom

Location

Ninewells Hospital

Dundee, DD1 9SY, United Kingdom

Location

Princess Alexandra Eye Pavilion

Edinburgh, EH1 3EG, United Kingdom

Location

Royal Children's Hospital

Glasgow, G51 4TF, United Kingdom

Location

James Paget University Hospitals NHS Foundation Trust

Great Yarmouth, NR31 6LA, United Kingdom

Location

Hull University Teaching Hospitals NHS Trust

Hull, HU3 2JZ, United Kingdom

Location

Leeds Teaching Hospitals NHS Trust

Leeds, LS9 7TF, United Kingdom

Location

Alder Hey Hospital NHS Foundation Trust

Liverpool, L12 2AP, United Kingdom

Location

Moorfields Eye Hospital NHS Foundation Trust

London, EC1V 2PD, United Kingdom

Location

Royal Free London NHS Foundation Trust

London, NW3 2QG, United Kingdom

Location

St Thomas' Hospital

London, SE1 7EH, United Kingdom

Location

Great Ormond Street Hospital NHS Foundation Trust

London, WC1N 3JH, United Kingdom

Location

Maidstone and Tunbridge Wells NHS Trust

Maidstone, ME16 9QQ, United Kingdom

Location

Manchester University NHS Foundation Trust

Manchester, M13 9WL, United Kingdom

Location

Newcastle Upon Tyne Hospitals NHS Foundation Trust

Newcastle, NE1 4LP, United Kingdom

Location

Norfolk and Norwich University Hospitals NHS Foundation Trust

Norwich, NR4 7UY, United Kingdom

Location

Nottingham University Hospitals NHS Trust

Nottingham, NG7 2UH, United Kingdom

Location

Oxford University Hospitals NHS Foundation Trust

Oxford, OX3 9DU, United Kingdom

Location

Sussex Eye Hospital and Royal Alexandra Children's Hospital

Redhill, RH1 5RH, United Kingdom

Location

Sheffield Children's Hospitals NHS Foundation Trust

Sheffield, S10 2TH, United Kingdom

Location

University Hospital Southampton NHS Foundation Trust

Southampton, SO16 6YD, United Kingdom

Location

Southend University Hospital NHS Foundation Trust

Westcliff-on-Sea, SS0 0RY, United Kingdom

Location

Royal London Hospital

Whitechapel, E1 1FR, United Kingdom

Location

York Teaching Hospital NHS Foundation Trust

York, YO31 8HE, United Kingdom

Location

Related Publications (1)

  • Kellett S, Rahi JS, Dick AD, Knowles R, Tadic V, Solebo AL. UNICORNS: Uveitis in childhood prospective national cohort study protocol. F1000Res. 2023 Aug 30;9:1196. doi: 10.12688/f1000research.26689.2. eCollection 2020.

    PMID: 38435080BACKGROUND

Related Links

Biospecimen

Retention: SAMPLES WITH DNA

Saliva, Stool, Tears and Blood

MeSH Terms

Conditions

Uveitis

Condition Hierarchy (Ancestors)

Uveal DiseasesEye Diseases

Study Officials

  • Ameenat L Solebo

    University College London (UCL) Great Ormond Street Institute of Child Health

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
10 Years
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 16, 2020

First Posted

May 23, 2022

Study Start

October 22, 2020

Primary Completion

December 1, 2025

Study Completion (Estimated)

December 1, 2026

Last Updated

October 4, 2024

Record last verified: 2024-09

Data Sharing

IPD Sharing
Will not share

Authorised collaborators will be granted access to aggregated anonymised data, following review of their research protocol study PI and Co-Is. Data and material transfer agreements will be required to be completed, in order to ensure regulatory compliance and that the interests of the participants are upheld and respected throughout.

Locations